35. Pemphigus Clinical trials / Disease details


Clinical trials : 98 Drugs : 126 - (DrugBank : 41) / Drug target genes : 23 - Drug target pathways : 168

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04422912
(ClinicalTrials.gov)
September 29, 20202/6/2020Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)A Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects With Active, Anti-DSG3, Mucosal-dominant Pemphigus VulgarisMucosal -Dominant Pemphigus VulgarisBiological: DSG3-CAARTCabaletta BioNULLRecruiting18 YearsN/AAll30Phase 1United States